Role for miR-204 in human pulmonary arterial hypertension

Journal of Experimental Medicine

Volumn 208, Issue 3, 2011, Pages 535-548

  Courboulin, Audrey ^a   Paulin, Roxane ^a   Giguère, Nellie J ^b   Saksouk, Nehmé ^b   Perreault, Tanya ^a   Meloche, Jolyane ^a   Paquet, Eric R ^a   Biardel, Sabrina ^c   Provencher, Steeve ^c   Côté, Jacques ^b   Simard, Martin J ^b   Bonnet, Sébastien ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRNA 204; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT3 PROTEIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; UPREGULATION;

EID: 79952733132     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20101812     Document Type: Article

References (67)

1. Archer, S., and S. Rich. 2000. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation. 102:2781-2791.
2. Banes-Berceli, A.K., P. Ketsawatsomkron, S. Ogbi, B. Patel, D.M. Pollock, and M.B. Marrero. 2007. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am. J. Physiol. Heart Circ. Physiol. 293:H1291-H1299. doi:10.1152/ajpheart.00181.2007 (Pubitemid 47254232)
3. Barman, S.A., S. Zhu, and R.E. White. 2009. RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension. Vasc. Health Risk Manag. 5:663-671. doi:10.2147/VHRM.S4711
4. Barst, R.J. 2005. PDGF signaling in pulmonary arterial hypertension. J. Clin. Invest. 115:2691-2694. doi:10.1172/JCI26593 (Pubitemid 41434394)
5. Bonnet, S., and S.L. Archer. 2007. Potassium channel diversity in the pulmonary arteries and pulmonary veins: implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension. Pharmacol. Ther. 115:56-69. doi:10.1016/j.pharmthera.2007.03.014 (Pubitemid 46992809)
6. Bonnet, S., E.D. Michelakis, C.J. Porter, M.A. Andrade-Navarro, B. Thébaud, S. Bonnet, A. Haromy, G. Harry, R. Moudgil, M.S. McMurtry, et al. 2006. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation. 113:2630-2641. doi:10.1161/CIRCULATIONAHA.105.609008 (Pubitemid 43948012)
7. Bonnet, S., S.L. Archer, J. Allalunis-Turner, A. Haromy, C. Beaulieu, R. Thompson, C.T. Lee, G.D. Lopaschuk, L. Puttagunta, S. Bonnet, et al. 2007a. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 11:37-51. doi:10.1016/j.ccr.2006.10.020 (Pubitemid 46054520)
8. Bonnet, S., G. Rochefort, G. Sutendra, S.L. Archer, A. Haromy, L. Webster, K. Hashimoto, S.N. Bonnet, and E.D. Michelakis. 2007b. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc. Natl. Acad. Sci. USA. 104:11418-11423. doi:10.1073/pnas.0610467104 (Pubitemid 47175155)
9. Bonnet, S., R. Paulin, G. Sutendra, P. Dromparis, M. Roy, K.O. Watson, J. Nagendran, A. Haromy, J.R. Dyck, and E.D. Michelakis. 2009. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-beta/NFAT axis. Circulation. 120:1231-1240. doi:10.1161/CIRCULATIONAHA.109.848911
10. Bourillot, P.Y., I. Aksoy, V. Schreiber, F. Wianny, H. Schulz, O. Hummel, N. Hubner, and P. Savatier. 2009. Novel STAT3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog. Stem Cells. 27:1760-1771. doi:10.1002/stem.110
11. Bregeon, J., G. Loirand, P. Pacaud, and M. Rolli-Derkinderen. 2009. Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 297:C1062-C1070. doi:10.1152/ajpcell.00174.2009
12. Brock, M., M. Trenkmann, R.E. Gay, B.A. Michel, S. Gay, M. Fischler, S. Ulrich, R. Speich, and L.C. Huber. 2009. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ. Res. 104:1184-1191. doi:10.1161/CIRCRESAHA.109. 197491
13. Caruso, P., M.R. MacLean, R. Khanin, J. McClure, E. Soon, M. Southgate, R.A. MacDonald, J.A. Greig, K.E. Robertson, R. Masson, et al. 2010. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler. Thromb. Vasc. Biol. 30:716-723. doi:10.1161/ATVBAHA.109.202028
14. Chen, X., H. Xu, P. Yuan, F. Fang, M. Huss, V.B. Vega, E. Wong, Y.L. Orlov, W. Zhang, J. Jiang, et al. 2008. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell. 133:1106-1117. doi:10.1016/j.cell.2008.04.043 (Pubitemid 351787745)
15. Cheranov, S.Y., M. Karpurapu, D. Wang, B. Zhang, R.C. Venema, and G.N. Rao. 2008. An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. Blood. 111:5581-5591. doi:10.1182/blood-2007-11- 126680
16. Christman, B.W., C.D. McPherson, J.H. Newman, G.A. King, G.R. Bernard, B.M. Groves, and J.E. Loyd. 1992. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327:70-75. doi:10.1056/NEJM199207093270202
17. Cowan, K.N., P.L. Jones, and M. Rabinovitch. 2000. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J. Clin. Invest. 105:21-34. doi:10.1172/JCI6539 (Pubitemid 30036384)
18. Doggrell, S.A. 2005. Rho-kinase inhibitors show promise in pulmonary hypertension. Expert Opin. Investig. Drugs. 14:1157-1159. doi:10.1517/13543784. 14.9.1157 (Pubitemid 41246170)
19. Dumas de la Roque, E., J.P. Savineau, and S. Bonnet. 2010. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacol. Ther. 126:186-199. doi:10.1016/j.pharmthera.2010.02.003
20. Dupuis, J., and M.M. Hoeper. 2008. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur. Respir. J. 31:407-415. doi:10.1183/09031936.00078207
21. Ferracin, M., A. Veronese, and M. Negrini. 2010. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev. Mol. Diagn. 10:297-308. doi:10.1586/erm.10.11
22. Fornaro, M., P.M. Burch, W. Yang, L. Zhang, C.E. Hamilton, J.H. Kim, B.G. Neel, and A.M. Bennett. 2006. SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth. J. Cell Biol. 175:87-97. doi:10.1083/jcb.200602029 (Pubitemid 44537201)
23. Frasch, H.F., C. Marshall, and B.E. Marshall. 1999. Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am. J. Physiol. 276:L304-L310. (Pubitemid 29102272)
24. Gharavi, N.M., J.A. Alva, K.P. Mouillesseaux, C. Lai, M. Yeh, W. Yeung, J. Johnson, W.L. Szeto, L. Hong, M. Fishbein, et al. 2007. Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J. Biol. Chem. 282:31460-31468. doi:10.1074/jbc.M704267200 (Pubitemid 350044874)
25. Ghofrani, H.A., W. Seeger, and F. Grimminger. 2005. Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 353:1412-1413. doi:10.1056/NEJMc051946 (Pubitemid 41362714)
26. Glazova, M., T.L. Aho, A. Palmetshofer, A. Murashov, M. Scheinin, and P.J. Koskinen. 2005. Pim-1 kinase enhances NFATc activity and neuroendocrine functions in PC12 cells. Brain Res. Mol. Brain Res. 138:116-123. doi:10.1016/j.molbrainres.2005.04.003 (Pubitemid 41138030)
27. Humbert, M., G. Monti, F. Brenot, O. Sitbon, A. Portier, L. Grangeot-Keros, P. Duroux, P. Galanaud, G. Simonneau, and D. Emilie. 1995. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 151:1628-1631.
28. Humbert, M., N.W. Morrell, S.L. Archer, K.R. Stenmark, M.R. MacLean, I.M. Lang, B.W. Christman, E.K. Weir, O. Eickelberg, N.F. Voelkel, and M. Rabinovitch. 2004. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43:S13-S24. doi:10.1016/j.jacc.2004.02.029
29. Ji, R., Y. Cheng, J. Yue, J. Yang, X. Liu, H. Chen, D.B. Dean, and C. Zhang. 2007. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ. Res. 100:1579-1588. doi:10.1161/CIRCRESAHA.106.141986 (Pubitemid 46897261)
30. Jurasz, P., D. Courtman, S. Babaie, and D.J. Stewart. 2010. Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials. Pharmacol. Ther. 126:1-8. doi:10.1016/j.pharmthera.2009.12.006
31. Katakami, N., H. Kaneto, H. Hao, Y. Umayahara, Y. Fujitani, K. Sakamoto, S. Gorogawa, T. Yasuda, D. Kawamori, Y. Kajimoto, et al. 2004. Role of pim-1 in smooth muscle cell proliferation. J. Biol. Chem. 279: 54742-54749. doi:10.1074/jbc.M409140200 (Pubitemid 40053219)
32. Khan, A.A., D. Betel, M.L. Miller, C. Sander, C.S. Leslie, and D.S. Marks. 2009. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat. Biotechnol. 27:549-555. doi:10.1038/nbt.1543
33. Kimura, K., and S. Eguchi. 2009. Angiotensin II type-1 receptor regulates RhoA and Rho-kinase/ROCK activation via multiple mechanisms. Focus on "Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells". Am. J. Physiol. Cell Physiol. 297:C1059-C1061. doi:10.1152/ajpcell.00399.2009
34. Latronico, M.V., and G. Condorelli. 2009. MicroRNAs and cardiac pathology. Nat Rev Cardiol. 6:418-429. doi:10.1038/nrcardio.2009.56
35. Lee, H.H., and Z.F. Chang. 2008. Regulation of RhoA-dependent ROCKII activation by Shp2. J. Cell Biol. 181:999-1012. doi:10.1083/jcb.200710187
36. Lee, Y., X. Yang, Y. Huang, H. Fan, Q. Zhang, Y. Wu, J. Li, R. Hasina, C. Cheng, M.W. Lingen, et al. 2010. Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLOS Comput. Biol. 6:e1000730. doi:10.1371/journal.pcbi.1000730
37. Li, B., L. Yang, J. Shen, C. Wang, and Z. Jiang. 2007. The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation. Anesth. Analg. 105:1034-1041. doi:10.1213/01.ane.0000278736.81133.26 (Pubitemid 47479318)
38. Li, J., X.L. Niu, and N.R. Madamanchi. 2008. Leukocyte antigen-related protein tyrosine phosphatase negatively regulates hydrogen peroxide-induced vascular smooth muscle cell apoptosis. J. Biol. Chem. 283:34260-34272. doi:10.1074/jbc.M806087200
39. Macian, F. 2005. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5:472-484. doi:10.1038/nri1632 (Pubitemid 40835035)
40. McMurtry, M.S., S.L. Archer, D.C. Altieri, S. Bonnet, A. Haromy, G. Harry, S. Bonnet, L. Puttagunta, and E.D. Michelakis. 2005. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. Invest. 115:1479-1491. doi:10.1172/JCI23203 (Pubitemid 40814657)
41. Mishra, P.K., N. Tyagi, M. Kumar, and S.C. Tyagi. 2009. MicroRNAs as a therapeutic target for cardiovascular diseases. J. Cell. Mol. Med. 13:778-789. doi:10.1111/j.1582-4934.2009.00744.x
42. Naylor, J., J. Li, C.J. Milligan, F. Zeng, P. Sukumar, B. Hou, A. Sedo, N. Yuldasheva, Y. Majeed, D. Beri, et al. 2010. Pregnenolone sulphate- and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle secretion and contraction. Circ. Res. 106:1507-1515. doi:10.1161/CIRCRESAHA.110.219329
43. Perros, F., D. Montani, P. Dorfmüller, I. Durand-Gasselin, C. Tcherakian, J. Le Pavec, M. Mazmanian, E. Fadel, S. Mussot, O. Mercier, et al. 2008. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178:81-88. doi:10.1164/rccm.200707-1037OC (Pubitemid 351919196)
44. Platoshyn, O., V.A. Golovina, C.L. Bailey, A. Limsuwan, S. Krick, M. Juhaszova, J.E. Seiden, L.J. Rubin, and J.X. Yuan. 2000. Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am. J. Physiol. Cell Physiol. 279:C1540-C1549.
45. Rainio, E.M., J. Sandholm, and P.J. Koskinen. 2002. Cutting edge: Transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J. Immunol. 168:1524-1527. (Pubitemid 34135742)
46. Rajkumar, R., K. Konishi, T.J. Richards, D.C. Ishizawar, A.C. Wiechert, N. Kaminski, and F. Ahmad. 2010. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am. J. Physiol. Heart Circ. Physiol. 298:H1235-H1248. doi:10.1152/ajpheart.00254.2009
47. Sakao, S., L. Taraseviciene-Stewart, J.D. Lee, K. Wood, C.D. Cool, and N.F. Voelkel. 2005. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J. 19:1178-1180. (Pubitemid 40946457)
48. Sato, K., T. Nagao, M. Kakumoto, M. Kimoto, T. Otsuki, T. Iwasaki, A.A. Tokmakov, K. Owada, and Y. Fukami. 2002. Adaptor protein Shc is an isoform-specific direct activator of the tyrosine kinase c-Src. J. Biol. Chem. 277:29568-29576. doi:10.1074/jbc.M203179200 (Pubitemid 41079245)
49. Shibata, R., H. Kai, Y. Seki, S. Kato, Y. Wada, Y. Hanakawa, K. Hashimoto, A. Yoshimura, and T. Imaizumi. 2003. Inhibition of STAT3 prevents neointima formation by inhibiting proliferation and promoting apoptosis of neointimal smooth muscle cells. Hum. Gene Ther. 14:601-610. doi:10.1089/ 104303403321618128 (Pubitemid 36543433)
50. Steiner, M.K., O.L. Syrkina, N. Kolliputi, E.J. Mark, C.A. Hales, and A.B. Waxman. 2009. Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 104:236-244. doi:10.1161/CIRCRESAHA.108.182014
51. Steudel, W., F. Ichinose, P.L. Huang, W.E. Hurford, R.C. Jones, J.A. Bevan, M.C. Fishman, and W.M. Zapol. 1997. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ. Res. 81:34-41. (Pubitemid 27272980)
52. Stewart, D.J., R.D. Levy, P. Cernacek, and D. Langleben. 1991. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann. Intern. Med. 114:464-469.
53. Tada, Y., S. Majka, M. Carr, J. Harral, D. Crona, T. Kuriyama, and J. West. 2007. Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic mouse model of PAH. Am. J. Physiol. Lung Cell. Mol. Physiol. 292:L1556-L1563. doi:10.1152/ajplung.00305.2006 (Pubitemid 47077371)
54. Todorovich-Hunter, L., D.J. Johnson, P. Ranger, F.W. Keeley, and M. Rabinovitch. 1988. Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline. A biochemical and ultrastructural study. Lab. Invest. 58:184-195. (Pubitemid 18075280)
55. Tuder, R.M., J.C. Marecki, A. Richter, I. Fijalkowska, and S. Flores. 2007. Pathology of pulmonary hypertension. Clin. Chest Med. 28:23-42: vii. doi:10.1016/j.ccm.2006.11.010
56. Wang, F.E., C. Zhang, A. Maminishkis, L. Dong, C. Zhi, R. Li, J. Zhao, V. Majerciak, A.B. Gaur, S. Chen, and S.S. Miller. 2010. MicroRNA-204/211 alters epithelial physiology. FASEB J. 24:1552-1571. doi:10.1096/fj.08-125856
57. Wang, L., D. Xu, W. Dai, and L. Lu. 1999. An ultraviolet-activated K+ channel mediates apoptosis of myeloblastic leukemia cells. J. Biol. Chem. 274:3678-3685. doi:10.1074/jbc.274.6.3678 (Pubitemid 29077213)
58. Wong, W.K., J.A. Knowles, and J.H. Morse. 2005. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 33:438-446. doi:10.1165/rcmb.2005-0103OC (Pubitemid 41572686)
59. Wu, J.H., R. Goswami, X. Cai, S.T. Exum, X. Huang, L. Zhang, L. Brian, R.T. Premont, K. Peppel, and N.J. Freedman. 2006. Regulation of the platelet- derived growth factor receptor-beta by G protein-coupled receptor kinase-5 in vascular smooth muscle cells involves the phosphatase Shp2. J. Biol. Chem. 281:37758-37772. doi:10.1074/jbc.M605756200 (Pubitemid 46042079)
60. Yellaturu, C.R., and G.N. Rao. 2003. Cytosolic phospholipase A2 is an effector of Jak/STAT signaling and is involved in platelet-derived growth factor BB-induced growth in vascular smooth muscle cells. J. Biol. Chem. 278:9986-9992. doi:10.1074/jbc.M211276200 (Pubitemid 36800504)
61. Yildiz, P. 2009. Molecular mechanisms of pulmonary hypertension. Clin. Chim. Acta. 403:9-16. doi:10.1016/j.cca.2009.01.018
62. Yu, Y., M. Sweeney, S. Zhang, O. Platoshyn, J. Landsberg, A. Rothman, and J.X. Yuan. 2003. PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am. J. Physiol. Cell Physiol. 284:C316-C330. (Pubitemid 36120070)
63. Yu, Y., I. Fantozzi, C.V. Remillard, J.W. Landsberg, N. Kunichika, O. Platoshyn, D.D. Tigno, P.A. Thistlethwaite, L.J. Rubin, and J.X. Yuan. 2004. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc. Natl. Acad. Sci. USA. 101:13861-13866. doi:10.1073/pnas.0405908101 (Pubitemid 39298498)
64. Yuan, X.J. 1995. Voltage-gated K+ currents regulate resting membrane potential and [Ca2+]i in pulmonary arterial myocytes. Circ. Res. 77:370-378.
65. Zakrzewicz, A., M. Hecker, L.M. Marsh, G. Kwapiszewska, B. Nejman, L. Long, W. Seeger, R.T. Schermuly, N.W. Morrell, R.E. Morty, and O. Eickelberg. 2007. Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension. Circulation. 115:2957-2968. doi:10.1161/CIRCULATIONAHA.106.670026 (Pubitemid 46912099)
66. Zhang, C. 2009. MicroRNA-145 in vascular smooth muscle cell biology: a new therapeutic target for vascular disease. Cell Cycle. 8:3469-3473. doi:10.4161/cc.8.21.9837
67. Zhao, L., R. al-Tubuly, A. Sebkhi, A.A. Owji, D.J. Nunez, and M.R. Wilkins. 1996. Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung. Br. J. Pharmacol. 119:1217-1222.